PRAX

Praxis Precision Medicines, Inc.

NasdaqAdd to watchlist

Healthcare · Biotechnology

$298.95

−$11.52−3.71%

Delayed · 2026-09-18T20:00:00.000Z · marketstack

1 of 4 open-market sales on file ran under a pre-arranged trading plan ($3.61M), 3 did not. Who, and when

Aug 24, 2026$298.95

−$69.08−18.77%over 1M

Session

Day range18% of range

$295.71$314.01

Fundamentals

Visualize fundamentals and more

Market cap: 8.71B
P/E ratio: -

Revenue grew −100.00% in FY2025, +108.87% slower than its sector. The median across Healthcare companies this platform tracks is +8.87%.

Risk factors, year on year

Item 1AFeb 2026 10-KFeb 2025

added: 56
dropped: 62
re-drafted: 43

Out of 300 passages in this year’s Item 1A.

New this year

• prepare for potential commercialization of our product candidates, including market research, pricing and reimbursement strategy development, market access planning, and other commercial readiness activities;

117 more passages are on Bespoke

Bespoke Create a free account

Free, no card, and it does not expire. See what the paid plans add

What it says it is exposed to

From Item 1A of its most recent 10-K, filed February 2026.

FDA approval
Reimbursement
Litigation
Data privacy
Patent expiry
Product recalls
Export controls
Going concern

And 9 more.

FDA approval
Food and Drug Administration, or the FDA, or other regulatory authorities to perform clinical trials in addition to those that we currently expect, or if there are any delays in establishing appropriate manufacturing arrangements for or in completing our …

7 more themes are on Measure

Measure Create a free account

Free, no card, and it does not expire. See what the paid plans add

Recent activity

30 more events are on Measure

Measure Create a free account

Free, no card, and it does not expire. See what the paid plans add

Discussion

No comments yet

Set a username to join the discussion. It’s the only thing shown next to what you post, never your email address.

Comments are written by other users. Nothing here is investment advice and nothing is checked for accuracy.

Updated Sep 18, 2026 · the last close

Praxis Precision Medicines, Inc. investor relations

What PRAX has filed with the SEC. This is not Praxis Precision Medicines, Inc.’s own investor relations site: these filings are the primary source that site publishes from.

Companies like Praxis Precision Medicines, Inc.

Also filed under Biotechnology, ranked by how closely they sit beside PRAX.

MRNAModerna, Inc.compare with PRAX
ROIVRoivant Sciences Ltd.compare with PRAX
VRTX

Vertex Pharmaceuticals Inc. / MA

XENEXenon Pharmaceuticals Inc.compare with PRAX

NVONovo Nordisk A Scompare with PRAX

Ask about Praxis Precision Medicines, Inc.

The assistant answers from what PRAX has actually filed: 7 annual reports filed with the SEC, 84 Form 4 filings from the last year and 4 funds that hold it. Every figure in a reply links to the filing it came from, so an answer can be checked rather than believed.

Press one and the answer appears right here on the page, from PRAX's filings and figures. One a day without an account; a free account has its own, and no card.

See how much of Praxis Precision Medicines, Inc. each of these investors holds, and every quarter they moved.

Ten seconds. No card. Nothing to cancel.

No card, no broker connection.

Continue with Google

What an account lets you do with Praxis Precision Medicines, Inc.

Be told the moment a PRAX insider trades
Put Praxis Precision Medicines, Inc. on a watchlist for a free alert, the bell and a daily email, when a Form 4 worth a row is filed, with vesting and automatic tax sales already struck out so what lands is a decision, not paperwork.
The full filing historyMeasure
Ask what growth the price is already betting on
Praxis Precision Medicines, Inc.'s income statement, balance sheet and cash flow as filed, and the ratios computed from them, plus a reverse DCF that holds today's price fixed and solves for the growth it requires.
The reverse DCFMeasure
Watch the same stakes the professionals are watching
Every tracked position priced at the quarter it was filed and diffed against the one before it: how big a bet each one is, and by how much it changed.
Every position, sizedMeasure
Interrogate the filing, not the internet
Ask anything about Praxis Precision Medicines, Inc.'s fundamentals. The assistant answers from its own filings and cites the figure, never a guess from the open web.

Create a free account See what the paid plans add

Free, no card, and it does not expire.

Risk factors, year on year

Item 1AFeb 2026 10-KFeb 2025

added: 56
dropped: 62
re-drafted: 43

Out of 300 passages in this year’s Item 1A.

New this year

• prepare for potential commercialization of our product candidates, including market research, pricing and reimbursement strategy development, market access planning, and other commercial readiness activities;

117 more passages are on Bespoke

Bespoke Create a free account

Free, no card, and it does not expire. See what the paid plans add

What it says it is exposed to

From Item 1A of its most recent 10-K, filed February 2026.

FDA approval
Reimbursement
Litigation
Data privacy
Patent expiry
Product recalls
Export controls
Going concern

And 9 more.

FDA approval
Food and Drug Administration, or the FDA, or other regulatory authorities to perform clinical trials in addition to those that we currently expect, or if there are any delays in establishing appropriate manufacturing arrangements for or in completing our …

7 more themes are on Measure

Measure Create a free account

Free, no card, and it does not expire. See what the paid plans add